The present and future disease burden of hepatitis C virus infections with today's treatment paradigm - volume 3.

The present and future disease burden of hepatitis C virus infections with today's treatment paradigm - volume 3.

Sibley, A;Han, K H;Abourached, A;Lesmana, L A;Makara, M;Jafri, W;Salupere, R;Assiri, A M;Goldis, A;Abaalkhail, F;Abbas, Z;Abdou, A;Al Braiki, F;Al Hosani, F;Al Jaberi, K;Al Khatry, M;Al Mulla, M A;Al Quraishi, H;Al Rifai, A;Al Serkal, Y;Alam, A;Alavian, S M;Alashgar, H I;Alawadhi, S;Al-Dabal, L;Aldins, P;Alfaleh, F Z;Alghamdi, A S;Al-Hakeem, R;Aljumah, A A;Almessabi, A;Alqutub, A N;Alswat, K A;Altraif, I;Alzaabi, M;Andrea, N;Babatin, M A;Baqir, A;Barakat, M T;Bergmann, O M;Bizri, A R;Blach, S;Chaudhry, A;Choi, M S;Diab, T;Djauzi, S;El Hassan, E S;El Khoury, S;Estes, C;Fakhry, S;Farooqi, J I;Fridjonsdottir, H;Gani, R A;Ghafoor Khan, A;Gheorghe, L;Gottfredsson, M;Gregorcic, S;Gunter, J;Hajarizadeh, B;Hamid, S;Hasan, I;Hashim, A;Horvath, G;Hunyady, B;Husni, R;Jeruma, A;Jonasson, J G;Karlsdottir, B;Kim, D Y;Kim, Y S;Koutoubi, Z;Liakina, V;Lim, Y S;Löve, A;Maimets, M;Malekzadeh, R;Matičič, M;Memon, M S;Merat, S;Mokhbat, J E;Mourad, F H;Muljono, D H;Nawaz, A;Nugrahini, N;Olafsson, S;Priohutomo, S;Qureshi, H;Rassam, P;Razavi, H;Razavi-Shearer, D;Razavi-Shearer, K;Rozentale, B;Sadik, M;Saeed, K;Salamat, A;Sanai, F M;Sanityoso Sulaiman, A;Sayegh, R A;Sharara, A I;Siddiq, M;Siddiqui, A M;Sigmundsdottir, G;Sigurdardottir, B;Speiciene, D;Sulaiman, A;Sultan, M A;Taha, M;Tanaka, J;Tarifi, H;Tayyab, G;Tolmane, I;Ud Din, M;Umar, M;Valantinas, J;Videčnik-Zorman, J;Yaghi, C;Yunihastuti, E;Yusuf, M A;Zuberi, B F;Schmelzer, J D;
journal of viral hepatitis 2015 Vol. 22 Suppl 4 pp. 21-41
346
sibley2015thejournal

Abstract

The total number, morbidity and mortality attributed to viraemic hepatitis C virus (HCV) infections change over time making it difficult to compare reported estimates from different years. Models were developed for 15 countries to quantify and characterize the viraemic population and forecast the changes in the infected population and the corresponding disease burden from 2014 to 2030. With the exception of Iceland, Iran, Latvia and Pakistan, the total number of viraemic HCV infections is expected to decline from 2014 to 2030, but the associated morbidity and mortality are expected to increase in all countries except for Japan and South Korea. In the latter two countries, mortality due to an ageing population will drive down prevalence, morbidity and mortality. On the other hand, both countries have already experienced a rapid increase in HCV-related mortality and morbidity. HCV-related morbidity and mortality are projected to increase between 2014 and 2030 in all other countries as result of an ageing HCV-infected population. Thus, although the total number of HCV countries is expected to decline in most countries studied, the associated disease burden is expected to increase. The current treatment paradigm is inadequate if large reductions in HCV-related morbidity and mortality are to be achieved.

Citation

ID: 55097
Ref Key: sibley2015thejournal
Use this key to autocite in SciMatic or Thesis Manager

References

Blockchain Verification

Account:
NFT Contract Address:
0x95644003c57E6F55A65596E3D9Eac6813e3566dA
Article ID:
55097
Unique Identifier:
10.1111/jvh.12476
Network:
Scimatic Chain (ID: 481)
Loading...
Blockchain Readiness Checklist
Authors
Abstract
Journal Name
Year
Title
5/5
Creates 1,000,000 NFT tokens for this article
Token Features:
  • ERC-1155 Standard NFT
  • 1 Million Supply per Article
  • Transferable via MetaMask
  • Permanent Blockchain Record
Blockchain QR Code
Scan with Saymatik Web3.0 Wallet

Saymatik Web3.0 Wallet